Corrado Advisors LLC reduced its holdings in BlackRock Health Sciences Term Trust (NYSE:BMEZ – Free Report) by 25.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,617 shares of the company’s stock after selling 3,908 shares during the period. Corrado Advisors LLC’s holdings in BlackRock Health Sciences Term Trust were worth $170,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in BMEZ. Carmel Capital Partners LLC purchased a new position in shares of BlackRock Health Sciences Term Trust during the 3rd quarter worth about $92,000. Stratos Wealth Advisors LLC purchased a new position in shares of BlackRock Health Sciences Term Trust during the 4th quarter worth about $170,000. CWM LLC boosted its stake in shares of BlackRock Health Sciences Term Trust by 1,212,300.0% during the 4th quarter. CWM LLC now owns 12,124 shares of the company’s stock worth $178,000 after purchasing an additional 12,123 shares during the period. Blue Bell Private Wealth Management LLC boosted its stake in shares of BlackRock Health Sciences Term Trust by 229.3% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 14,792 shares of the company’s stock worth $213,000 after purchasing an additional 10,300 shares during the period. Finally, Ieq Capital LLC purchased a new position in shares of BlackRock Health Sciences Term Trust during the 3rd quarter worth about $223,000.
BlackRock Health Sciences Term Trust Price Performance
Shares of BMEZ stock traded up 0.19 during trading hours on Tuesday, reaching 14.77. 173,500 shares of the stock were exchanged, compared to its average volume of 329,938. BlackRock Health Sciences Term Trust has a 12-month low of 12.93 and a 12-month high of 16.59. The company’s 50-day moving average price is 15.91 and its 200-day moving average price is 14.94.
BlackRock Health Sciences Term Trust Dividend Announcement
Insider Buying and Selling
In related news, major shareholder Saba Capital Management, L.P. acquired 46,421 shares of the stock in a transaction on Monday, April 1st. The stock was bought at an average cost of 16.33 per share, with a total value of 758,054.93. Following the transaction, the insider now directly owns 20,538,431 shares in the company, valued at 335,392,578.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders bought 2,055,802 shares of company stock valued at $32,347,047.
BlackRock Health Sciences Term Trust Profile
BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.
Read More
- Five stocks we like better than BlackRock Health Sciences Term Trust
- Do ETFs Pay Dividends? What You Need to Know
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Are Penny Stocks a Good Fit for Your Portfolio?
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Manufacturing Stocks Investing
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for BlackRock Health Sciences Term Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlackRock Health Sciences Term Trust and related companies with MarketBeat.com's FREE daily email newsletter.